Class Action Filed Against Replimune Over Alleged Securities Law Violations

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Replimune Group, Inc., on behalf of investors who purchased or otherwise acquired the company's securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune's statements about its business, operations, and prospects were materially false and misleading due to significant deficiencies in its clinical trial data.

According to the complaint, Replimune failed to address study design concerns previously communicated by the Food and Drug Administration (FDA) in connection with its Biologics License Application (BLA). Additionally, the company submitted data from an early, unplanned analysis of RP1-104 that included only 40 patients, representing approximately 10% of the planned enrollment of 400 patients. This early and incomplete data, the lawsuit asserts, likely caused the FDA to reject the BLA.

Bronstein, Gewirtz & Grossman, LLC, emphasizes that the complaint seeks to recover damages for investors who suffered losses due to these alleged securities law violations. Interested investors are encouraged to visit the firm's website at [bgandg.com/cases/replimune-group-inc-repl-class_action_lawsuit](bgandg.com/cases/replimune-group-inc-repl-class_action_lawsuit) for more information. The firm notes that investors who purchased or otherwise acquired Replimune securities during the class period have until October 5, 2026, to request that the court appoint them as lead plaintiff.

The lawsuit highlights the importance of transparency and accurate disclosure in the pharmaceutical industry. Bronstein, Gewirtz & Grossman, LLC, asserts that the deficiencies in Replimune's clinical trial data could have significant implications for the company's future prospects and investor confidence.

The firm's managing partner, Peretz Bronstein, states, "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace." Investors who believe they may be eligible to participate in the lawsuit are urged to contact the firm for further guidance.

This class action lawsuit comes as Replimune faces increased scrutiny over its clinical trials and the potential impact on its business. The allegations, if proven, could result in substantial financial and reputational damage to the company.